Abstract

BackgroundThe risk of thromboembolic events is higher among cancer patients, especially in patients undergoing chemotherapy. Cisplatin-based regimens claim to be associated with a very high thromboembolic rate. In this study, we report on our own experience with thrombosis among patients on active cisplatin-based chemotherapy.MethodsMedical records and hospital databases were searched for all the patients treated with any cisplatin-based regimen for any kind of cancer. Thrombosis was considered cisplatin-related if diagnosed any time after the first dose and up to 4 weeks after the last. The Khorana risk assessment model was performed in all cases.ResultsA total of 1677 patients (65.5% males, median age: 50 years) treated with cisplatin-based regimens were identified. Head and neck (22.9%), lung (22.2%), lymphoma and gastric (11.4% each) were the most common primary tumors. Thromboembolic events were reported in 110 (6.6%); the highest was in patients with gastric cancer (20.9%) and the lowest in patients with head and neck cancers (2.3%) and lymphoma (1.6%). Thrombosis included deep vein thrombosis (DVT) in 69 (62.7%), pulmonary embolism (PE) in 18 (16.9%) and arterial thrombosis in 17 (15.6%). A majority (51.1%) of the patients had stage IV disease and only 16% had stage I or II.In a multivariate analysis, significantly higher rates of thrombosis were associated with gastric as the primary tumor, advanced-stage disease, female sex but not age, and the Khorana risk score or type of cisplatin regimen. While the presence of CVC was significantly associated with the risk of thrombosis (p < 0.0001) in the univariate analysis, and such significance was lost in the multivariate analysis (odds ratio, 1.098; 95%CI, 0.603–1.999, p = 0.7599).ConclusionsThromboembolic events in cancer patients on active cisplatin-based chemotherapy were commonly encountered. Gastric cancer, regardless of other clinical variables, was associated with the highest risk.

Highlights

  • The risk of thromboembolic events is higher among cancer patients, especially in patients undergoing chemotherapy

  • Venous thromboembolism (VTE) and, to a lesser extent, arterial thrombosis are common complications encountered in patients with cancer during the course of their treatment and follow-up [1, 2]

  • 25 cases of myocardial infarction (MI) and cerebrovascular accidents (CVA) were reported among a group of young patients treated with cisplatin-based regimens for testicular cancer

Read more

Summary

Introduction

The risk of thromboembolic events is higher among cancer patients, especially in patients undergoing chemotherapy. Venous thromboembolism (VTE) and, to a lesser extent, arterial thrombosis are common complications encountered in patients with cancer during the course of their treatment and follow-up [1, 2]. Much of this high risk is attributed to the cancer itself or its therapy. Cisplatin is an old chemotherapeutic drug that was licensed in 1978 and is listed on the World Health Organization’s list of essential medicines It is widely used, alone or in combination, to treat a number of cancers, including testicular, ovarian, cervical, bladder, head and neck, lung, esophageal and gastric cancers [9, 10]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call